(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
IDF drops over 80 explosives on Tehran weapon production sites in latest strike - 2What to know about King Charles III's cancer treatment and his message to the public
- 3Could the Star of Bethlehem have actually been a comet?
- 4Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure
- 5The Most Famous Virtual Entertainment Powerhouses of the Year
- Figure out How to Involve a Brain science Certification in Showcasing
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- Manual for Purchasing a Modest Jeep Wrangler for Seniors
- 6 Top Computer game Control center
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Heartfelt Objections to Visit with Your Adored One
- Activist vessel collides with krill trawler in Antarctic confrontation
- Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
